The market’s harsh reaction to the Q4 miss seems unreasonable
08/02/24 -"Even though Q4 profitability fell short of the street’s expectations, the 2023 results met the management’s CER guidance. The management’s 2024 outlook was healthy as well. Still, the share price ..."
Pages
65
Language
English
Published on
08/02/24
You may also be interested by these reports :
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...